Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.

Adolescent Adult Anilides / adverse effects Animals Disease Models, Animal Female Genes, Neurofibromatosis 1 Humans Male Mice Mice, Mutant Strains Neurofibroma, Plexiform / drug therapy Neurofibromatosis 1 / drug therapy Pain Measurement Prospective Studies Protein Kinase Inhibitors / adverse effects Pyridines / adverse effects Quality of Life Receptor Protein-Tyrosine Kinases / antagonists & inhibitors Translational Research, Biomedical Young Adult

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
01 2021
Historique:
received: 19 12 2019
accepted: 25 11 2020
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 23 1 2021
Statut: ppublish

Résumé

Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicellular neoplasms that cause morbidity and may transform to sarcoma. Treatment of Nf1

Identifiants

DOI: 10.1038/s41591-020-01193-6 PMID: 33442015 PMC: PMC8275010
pubmed: 33442015
doi: 10.1038/s41591-020-01193-6
pii: 10.1038/s41591-020-01193-6
pmc: PMC8275010
mid: NIHMS1705876
doi:

Substances chimiques

Anilides 0
Protein Kinase Inhibitors 0
Pyridines 0
cabozantinib 1C39JW444G
Receptor Protein-Tyrosine Kinases EC 2.7.10.1

Banques de données

ClinicalTrials.gov
['NCT02101736']

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-173

Subventions

Organisme : US Army Medical Research and Development Command
ID : W81XWH-12-01-0155
Pays : International
Organisme : NCI NIH HHS
ID : U54 CA196519
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ID : K12-HD000850
Pays : International
Organisme : NICHD NIH HHS
ID : K12 HD000850
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : U54-CA196519-04
Pays : International

Investigateurs

Chie-Schin Shih (CS)
Amy E Armstrong (AE)

Références

PhRMA. A Decade of Innovation In Rare Diseases. http://phrma-docs.phrma.org/sites/default/files/pdf/PhRMA-Decade-of-Innovation-Rare-Diseases.pdf (2015).
Friedman, J. M. Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89, 1–6 (1999).
pubmed: 10469430 doi: 10.1002/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8
Wallace, M. R. et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181–186 (1990).
pubmed: 2134734 doi: 10.1126/science.2134734
Viskochil, D. et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187–192 (1990).
pubmed: 1694727 doi: 10.1016/0092-8674(90)90252-A
Ballester, R. et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851–859 (1990).
pubmed: 2121371 doi: 10.1016/0092-8674(90)90151-4
Gutmann, D. H., Blakeley, J. O., Korf, B. R. & Packer, R. J. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin. Investig. Drugs 22, 443–462 (2013).
pubmed: 23425047 pmcid: 4009992 doi: 10.1517/13543784.2013.772979
Maertens, O. et al. A collaborative model for accelerating the discovery and translation of cancer therapies. Cancer Res. 77, 5706–5711 (2017).
pubmed: 28993414 pmcid: 5668167 doi: 10.1158/0008-5472.CAN-17-1789
Packer, R. J., Fisher, M. J., Cutter, G., Cole-Plourde, K. & Korf, B. R. Neurofibromatosis Cinical Trial Consortium. J. Child Neurol. 33, 82–91 (2018).
pubmed: 29246097 doi: 10.1177/0883073817739196
Plotkin, S. R. et al. Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology 81, S1–S5 (2013).
pubmed: 24249801 pmcid: 3908338 doi: 10.1212/01.wnl.0000435743.49414.b6
Staser, K., Yang, F. C. & Clapp, D. W. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu. Rev. Pathol. 7, 469–495 (2012).
pubmed: 22077553 doi: 10.1146/annurev-pathol-011811-132441
Ferner, R. E. & Gutmann, D. H. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939–955 (2013).
pubmed: 23931823 doi: 10.1016/B978-0-444-52902-2.00053-9
Mautner, V. F. et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro. Oncol. 10, 593–598 (2008).
pubmed: 18559970 pmcid: 2666233 doi: 10.1215/15228517-2008-011
Gross, A. M. et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro. Oncol. 20, 1643–1651 (2018).
pubmed: 29718344 pmcid: 6231202 doi: 10.1093/neuonc/noy067
Evans, D. G. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311–314 (2002).
pubmed: 12011145 pmcid: 1735122 doi: 10.1136/jmg.39.5.311
Ratner, N. & Miller, S. J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 15, 290–301 (2015).
pubmed: 25877329 pmcid: 4822336 doi: 10.1038/nrc3911
Wentworth, S. et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int. J. Radiat. Oncol. Biol. Phys. 73, 208–213 (2009).
pubmed: 18687535 doi: 10.1016/j.ijrobp.2008.03.073
Greenberg, H. M. et al. Radiation therapy in the treatment of aggressive fibromatoses. Int. J. Radiat. Oncol. Biol. Phys. 7, 305–310 (1981).
pubmed: 6792167 doi: 10.1016/0360-3016(81)90102-4
Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375, 2550–2560 (2016).
pubmed: 28029918 pmcid: 5508592 doi: 10.1056/NEJMoa1605943
Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382, 1430–1442 (2020).
pubmed: 32187457 pmcid: 7305659 doi: 10.1056/NEJMoa1912735
Yang, F. C. et al. Nf1-dependent tumors require a microenvironment containing Nf1
pubmed: 18984156 pmcid: 2788814 doi: 10.1016/j.cell.2008.08.041
Munchhof, A. M. et al. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum. Mol. Genet. 15, 1858–1869 (2006).
pubmed: 16648142 doi: 10.1093/hmg/ddl108
Robertson, K. A. et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 13, 1218–1224 (2012).
pubmed: 23099009 pmcid: 5380388 doi: 10.1016/S1470-2045(12)70414-X
Rhodes, S. D. et al. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum. Mol. Genet. 28, 2752–2762 (2019).
Viola, D., Cappagli, V. & Elisei, R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol. 9, 1083–1092 (2013).
pubmed: 23902240 doi: 10.2217/fon.13.128
Cabozantinib approved for renal cell carcinoma. Cancer Discov. 6, OF3 (2016).
Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).
pubmed: 29972759 pmcid: 7523244 doi: 10.1056/NEJMoa1717002
Yakes, F. M. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298–2308 (2011).
pubmed: 21926191 doi: 10.1158/1535-7163.MCT-11-0264
Grullich, C. Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res. 211, 67–75 (2018).
pubmed: 30069760 doi: 10.1007/978-3-319-91442-8_5
Nguyen, L., Benrimoh, N., Xie, Y., Offman, E. & Lacy, S. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs 27, 669–678 (2016).
pubmed: 27139820 doi: 10.1097/CAD.0000000000000366
Armstrong, A. E. et al. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. Pediatr. Blood Cancer 67, e28372 (2020).
pubmed: 32459399 pmcid: 7516834 doi: 10.1002/pbc.28372
Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).
pubmed: 17721511 doi: 10.1038/nbt1328
Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307–321 (2012).
pubmed: 22500798 pmcid: 3328787 doi: 10.1016/j.cell.2012.02.053
Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).
Schoumacher, M. & Burbridge, M. Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. Curr. Oncol. Rep. 19, 19 (2017).
pubmed: 28251492 pmcid: 5332501 doi: 10.1007/s11912-017-0579-4
Dombi, E. et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81, S33–S40 (2013).
pubmed: 24249804 pmcid: 3908340 doi: 10.1212/01.wnl.0000435744.57038.af
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L. & Strom, B. L. Defining the clinically important difference in pain outcome measures. Pain 88, 287–294 (2000).
pubmed: 11068116 doi: 10.1016/S0304-3959(00)00339-0
Nutakki, K., Varni, J. W. & Swigonski, N. L. PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity. J. Neurooncol. 137, 337–347 (2018).
pubmed: 29273891 doi: 10.1007/s11060-017-2723-2
Pradhan, K. R. et al. Polychromatic flow cytometry identifies novel subsets of circulating cells with angiogenic potential in pediatric solid tumors. Cytometry B Clin. Cytom. 80, 335–338 (2011).
pubmed: 21567939 doi: 10.1002/cyto.b.20602
Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123, 340–347 (2013).
pubmed: 23221341 doi: 10.1172/JCI60578
Wu, J. et al. Preclincial testing of sorafenib and RAD001 in the Nf
pubmed: 21319287 doi: 10.1002/pbc.23015
Ferguson, M. J. et al. Preclinical evidence for the use of sunitinib malate in the treatment of plexiform neurofibromas. Pediatr. Blood Cancer 63, 206–213 (2016).
pubmed: 26375012 doi: 10.1002/pbc.25763
Gay, C. M., Balaji, K. & Byers, L. A. Giving AXL the axe: targeting AXL in human malignancy. Br. J. Cancer 116, 415–423 (2017).
pubmed: 28072762 pmcid: 5318970 doi: 10.1038/bjc.2016.428
Weiss, B. et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro. Oncol. 17, 596–603 (2015).
pubmed: 25314964 doi: 10.1093/neuonc/nou235
Jakacki, R. I. et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro. Oncol. 19, 289–297 (2017).
pubmed: 27510726
Dombi, E. et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 68, 643–647 (2007).
pubmed: 17215493 doi: 10.1212/01.wnl.0000250332.89420.e6
Lock, R. et al. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J. Clin. Invest. 126, 2181–2190 (2016).
pubmed: 27159396 pmcid: 4887164 doi: 10.1172/JCI85183
Choueiri, T. K. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J. Clin. Oncol. 35, 591–597 (2017).
pubmed: 28199818 doi: 10.1200/JCO.2016.70.7398
Cabanillas, M. E. et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial. J. Clin. Oncol. 35, 3315–3321 (2017).
pubmed: 28817373 pmcid: 5652872 doi: 10.1200/JCO.2017.73.0226
Tolaney, S. M. et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. Oncologist 22, 25–32 (2017).
pubmed: 27789775 pmcid: 5313267 doi: 10.1634/theoncologist.2016-0229
Yavuz, S. et al. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. Thyroid 24, 1223–1231 (2014).
pubmed: 24724719 pmcid: 4106376 doi: 10.1089/thy.2013.0621
Jousma, E. et al. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatr. Blood Cancer 62, 1709–1716 (2015).
pubmed: 25907661 pmcid: 4546559 doi: 10.1002/pbc.25546
Leibowitz-Amit, R. et al. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. J. Transl. Med. 14, 12 (2016).
pubmed: 26762579 pmcid: 4712499 doi: 10.1186/s12967-015-0747-y
Solomon, J., Warren, K., Dombi, E., Patronas, N. & Widemann, B. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput. Med. Imaging Graph. 28, 257–265 (2004).
pubmed: 15249071 doi: 10.1016/j.compmedimag.2004.03.002
Downie, W. W. et al. Studies with pain rating scales. Ann. Rheum. Dis. 37, 378–381 (1978).
pubmed: 686873 pmcid: 1000250 doi: 10.1136/ard.37.4.378
Cleeland, C. S. & Ryan, K. M. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singap. 23, 129–138 (1994).
pubmed: 8080219
Estes, M. L., Mund, J. A., Ingram, D. A. & Case, J. Identification of endothelial cells and progenitor cell subsets in human peripheral blood. Curr. Protoc. Cytom. 52, 9.33.1–9.33.11 (2010).
Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1–10 (1989).
pubmed: 2702835 doi: 10.1016/0197-2456(89)90015-9

Auteurs

Michael J Fisher (MJ)

Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
ORCID: 0000-0003-3408-3839

Chie-Schin Shih (CS)

Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Merck & Co., Inc., Kenilworth, NJ, USA.

Steven D Rhodes (SD)

Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Amy E Armstrong (AE)

Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, USA.

Pamela L Wolters (PL)

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

Eva Dombi (E)

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

Chi Zhang (C)

Department of Medical and Molecular Genomics, Indiana University, Indianapolis, IN, USA.

Steven P Angus (SP)

Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Department of Pharmacology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Department of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Gary L Johnson (GL)

Department of Pharmacology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

Roger J Packer (RJ)

Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington, DC, USA.

Jeffrey C Allen (JC)

Department of Pediatrics, New York University School of Medicine, New York, NY, USA.

Nicole J Ullrich (NJ)

Department of Neurology, Dana Farber/Boston Children's Hospital, Boston, MA, USA.

Stewart Goldman (S)

Division of Hematology/Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.

David H Gutmann (DH)

Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

Scott R Plotkin (SR)

Department of Neurology and Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.

Tena Rosser (T)

Division of Neurology, Children's Hospital of Los Angeles, Los Angeles, CA, USA.

Kent A Robertson (KA)

Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.

Brigitte C Widemann (BC)

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

Abbi E Smith (AE)

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Waylan K Bessler (WK)

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Yongzheng He (Y)

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Su-Jung Park (SJ)

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Julie A Mund (JA)

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Li Jiang (L)

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.

Khadijeh Bijangi-Vishehsaraei (K)

Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.

Coretta Thomas Robinson (CT)

Department of Biostatistics, University of Alabama Birmingham, Birmingham, AL, USA.

Gary R Cutter (GR)

Department of Biostatistics, University of Alabama Birmingham, Birmingham, AL, USA.

Bruce R Korf (BR)

Department of Genetics, University of Alabama Birmingham, Birmingham, AL, USA.

Jaishri O Blakeley (JO)

Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. jblakel3@jhmi.edu.

D Wade Clapp (DW)

Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA. dclapp@iu.edu.
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. dclapp@iu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Composés chimiques organiques › Amines › Dérivés de l'aniline › Anilides › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Eucaryotes › Animaux › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes suppresseurs de tumeur › Gènes nf1 › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Maladies du système nerveux › Maladies neuromusculaires › Neuropathies périphériques › Tumeurs du système nerveux périphérique › Tumeurs des gaines nerveuses › Neurofibrome › Neurofibrome plexiforme › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies génétiques congénitales › Syndromes néoplasiques héréditaires › Neurofibromatoses › Neurofibromatose de type 1 › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Examen physique › Examen neurologique › Mesure de la douleur › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs à activité tyrosine kinase › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Disciplines des sciences naturelles › Science › Recherche › Recherche biomédicale › Recherche médicale translationnelle › Cabozantinib for neurofibromatosis type...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Cabozantinib for neurofibromatosis type...